ABpro Announces Preclinical Data for Tetravalent Bispecific HER2xCD3 T-Cell Engager at AACR 2025
Abpro Holdings announced preclinical data for its HER2 x CD3 T-cell engager, ABP-102/CT-P72, will be presented at the American...
Quanta’s QTX3544: A Powerful New Oral Multi-KRAS Inhibitor
Quanta Therapeutics will present data on QTX3544, an oral, G12V-preferring, multi-KRAS inhibitor, at the 2025 AACR Annual Meeting. QTX3544...
Bolt Biotherapeutics Presents Promising BDC-1042 Data at AACR 2025
Bolt Biotherapeutics will present Phase 1 clinical trial data for BDC-3042, a dectin-2 agonist antibody targeting tumor-associated macrophages (TAMs),...
Polyrizon’s Pioneering Epilepsy Rescue Treatment Shows Promising Preclinical Results
Polyrizon Ltd. has initiated preclinical studies for intranasal delivery of benzodiazepines (BZDs) using its proprietary Trap and Target™ platform....
Corvus Pharmaceuticals 2024 Financial Results
Corvus Pharmaceuticals provided a business update and announced its financial results for the fourth quarter and year ending December...
Wrapsody CIE 12-Month Efficacy Results Released
Merit Medical Systems announced positive six and twelve-month results from the randomized arm of its WAVE trial, studying the...
Synthetic Data: A Real Fix for Clinical Trials?
The industry loves to celebrate synthetic data as a privacy solution—but where’s the real impact? Let’s be clear: privacy...
NeurOnos Secures $2M Funding for Innovative Autism Therapy
NeuroNOS, a Beyond Air subsidiary, secured $2 million in private equity funding to advance the preclinical development of a...
Alumis and Kaken Announce Licensing Agreement for Dermatology
Alumis and Kaken Pharmaceutical have partnered to develop and commercialize ESK-001, a selective TYK2 inhibitor, for dermatological conditions in...
Spark Biomedical: Neonatal Opioid Withdrawal Treatment Trial Enrollment Complete
Spark Biomedical has completed enrollment in its pivotal Phase II clinical trial for a non-invasive neurostimulation treatment for Neonatal...